![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » GSK’s COPD Treatment Bears Fruit in Phase 3
GSK’s COPD Treatment Bears Fruit in Phase 3
June 24, 2016
GlaxoSmithKline’s combination therapy for chronic obstructive pulmonary disease — fluticasone furoate, umeclidinium and vilanterol — shined in a Phase 3 study pitting it against the Symbicort Turbohaler.
The therapy met its two co-primary endpoints of statistical significance, compared to budesonide and formoterol, in enhancing lung function and quality of life in COPD patients.
Common adverse events linked to both treatment arms include nasopharyngitis, headache and COPD worsening, the company said.
Upcoming Events
-
21Oct